3.98

0.50% -0.02

NuCana plc ADR (NCNA)

Overview News Price History Discussions Forecast

NuCana plc ADR stock is currently priced at $3.98, with a 24-hour trading volume of 9,380. It has seen a -0.50% decreased in the last 24 hours and a +1,431% rose in the past month. The chart indicates a potential bullish trend, as the stock is above the $3.95 pivot point. If it approaches the $4.05 resistance level, significant changes may occur.

Previous Close:

$4.00

Open:

$4.14

24h Volume:

9,380

Market Cap:

$8.42M

Revenue:

Net Income/Loss:

$-34.33M

P/E Ratio:

-5.2757

EPS:

-0.7544

Net Cash Flow:

$-33.49M

1W Performance:

-0.25%

1M Performance:

+1,431%

6M Performance:

+729.08%

1Y Performance:

+368.79%

1D Range:

$3.96

$4.281

52W Range:

$0.1776

$5.14

NuCana plc ADR Stock (NCNA) Company Profile

Name

NuCana plc ADR

Sector

Healthcare (1203)

Industry

Biotechnology (688)

Phone

44 13 1357 1111

Address

3 Lochside Way, Edinburgh

Employee

Twitter

@NuCana_news

Next Earnings Date

2024-05-15

Latest SEC Filings

NCNA's Discussions on Twitter

NuCana plc ADR Stock (NCNA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-03-22	Downgrade	Cowen	Outperform → Market Perform
Oct-22-20	Initiated	Truist	Buy
Jul-24-20	Initiated	Oppenheimer	Outperform
Aug-19-19	Initiated	H.C. Wainwright	Buy
Oct-19-18	Initiated	Piper Jaffray	Overweight
Oct-23-17	Initiated	Citigroup	Buy
Oct-23-17	Initiated	Jefferies	Buy
Oct-23-17	Initiated	William Blair	Outperform

View All

NuCana plc ADR Stock (NCNA) Latest News

NuCana Presents Data at the AACR 2024 Annual Meeting Highlighting the Ability of NUC-7738 to Profoundly Alter Tumor Biology in a Paired Biopsy Clinical Study

GlobeNewswire Inc.

Why Kodiak Sciences Shares Are Trading Lower By Around 20%? Here Are Other Stocks Moving In Thursday's Mid-Day Session

Benzinga

Why RH Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket

Benzinga

NuCana Announces Plan to Implement ADS Ratio Change

GlobeNewswire Inc.

NuCana Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Business Update

GlobeNewswire Inc.

3 Technical Indicators to Use When Trading Penny Stocks

PennyStocks

NuCana plc ADR Stock (NCNA) Financials Data

NuCana plc ADR (NCNA) Net Income 2024

NCNA net income (TTM) was -$34.33 million for the quarter ending December 31, 2023, a +12.81% increase year-over-year.

NuCana plc ADR (NCNA) Cash Flow 2024

NCNA recorded a free cash flow (TTM) of -$33.49 million for the quarter ending December 31, 2023, a -14.24% decrease year-over-year.

NuCana plc ADR (NCNA) Earnings per Share 2024

NCNA earnings per share (TTM) was -$0.6584 for the quarter ending December 31, 2023, a +12.17% growth year-over-year.

NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of products for the treatment of cancer. The company develops its products based on its proprietary ProTide technology. Its lead product candidate includes Acelarin, which is in Phase I clinical trial for patients with advanced solid tumors; Phase Ib for patients with recurrent ovarian cancer; Phase Ib clinical trials for the treatment of patients with biliary tract cancer; Phase II clinical trial for the treatment of patients with platinum-resistant ovarian cancer; and Phase III clinical trial for the treatment of patients with pancreatic cancer. The company is also developing NUC-3373, a ProTide transformation of the active anti-cancer metabolite of 5-fluorouracil, which is in Phase I clinical trial for the treatment of patients with advanced solid tumors and in a Phase 1b/2 clinical trial for patients with advanced colorectal cancer; and NUC-7738, a nucleoside analog that is in Phase 1/2 clinical trial for the treatment of patients with advanced solid tumors and hematological tumors. It has a research, collaboration, and license agreement with Cardiff University and University College Cardiff Consultants Ltd. for the design, synthesis, characterization, and evaluation of ProTides; and an assignment, license, and collaboration agreement with Cardiff ProTides Ltd. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. NuCana plc was incorporated in 1997 and is headquartered in Edinburgh, the United Kingdom.